title: Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier.
abstract: Anti-microRNA oligonucleotides (AMOs) are steric blocking antisense reagents that inhibit microRNA (miRNA) function by hybridizing and repressing the activity of a mature miRNA. First generation AMOs employed 2'-O-Methyl RNA nucleotides (2'OMe) with phosphorothioate (PS) internucleotide linkages positioned at both ends to block exonuclease attack. Second generation AMOs improved potency through the use of chemical modifications that increase binding affinity to the target, such as locked nucleic acid (LNA) residues. However, this strategy can reduce specificity as high binding affinity compounds can bind to and suppress function of related sequences even if one or more mismatches are present. Further, unnatural modified nucleic acid residues can have toxic side effects. In the present study, a variety of non-nucleotide modifiers were screened for utility in steric blocking antisense applications. A novel compound, N,N-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine ("ZEN"), was discovered that increased binding affinity and blocked exonuclease degradation when placed at or near each end of a single-stranded oligonucleotide. This new modification was combined with the 2'OMe RNA backbone to make ZEN-AMOs. The new ZEN-AMOs have high potency and can effectively inhibit miRNA function in vitro at low nanomolar concentrations, show high specificity, and have low toxicity in cell culture.Molecular Therapy-Nucleic Acids (2013) 2, e117; doi:10.1038/mtna.2013.46; published online 27 August 2013.
authors: Integrated DNA Technologies, Inc., 1710 Commercial Park, Coralville, Iowa City, USA.
authors: Kim A
authors: KA
authors: Lennox
authors: Richard
authors: R
authors: Owczarzy
authors: Derek M
authors: DM
authors: Thomas
authors: Joseph A
authors: JA
authors: Walder
authors: Mark A
authors: MA
authors: Behlke
references: Nucleic Acids Res. 2010 Nov;38(20):7100-11
references: 20615897
references: Cell. 2009 Feb 20;136(4):642-55
references: 19239886
references: Nature. 2005 Mar 31;434(7033):663-6
references: 15800628
references: Nucleic Acids Res. 1993 Jun 11;21(11):2729-35
references: 8392706
references: Gene Ther. 2011 Dec;18(12):1111-20
references: 21753793
references: Antisense Res Dev. 1991 Summer;1(2):141-51
references: 1841656
references: Science. 1993 Jun 4;260(5113):1510-3
references: 7684856
references: Curr Opin Struct Biol. 1995 Jun;5(3):343-55
references: 7583633
references: Mol Ther. 2006 Mar;13(3):494-505
references: 16343994
references: Nature. 2008 Apr 17;452(7189):896-9
references: 18368051
references: Nucleic Acids Res. 1989 Jun 12;17(11):4255-73
references: 2472605
references: Biopolymers. 1987 Sep;26(9):1601-20
references: 3663875
references: J Immunol. 2000 Jan 15;164(2):944-53
references: 10623843
references: Nature. 2011 Oct 19;478(7369):404-7
references: 22012398
references: Eur J Biochem. 1974 Mar 1;42(2):495-504
references: 4597847
references: Silence. 2012 Jan 09;3(1):1
references: 22230293
references: RNA. 2008 Feb;14(2):336-46
references: 18073344
references: RNA. 2007 May;13(5):723-30
references: 17400817
references: Oligonucleotides. 2006 Spring;16(1):26-42
references: 16584293
references: Chem Rev. 2006 Aug;106(8):3443-67
references: 16895336
references: Oligonucleotides. 2009 Mar;19(1):1-13
references: 19125639
references: Nature. 2005 Dec 1;438(7068):685-9
references: 16258535
references: Nucleic Acids Res. 2008 Mar;36(4):1153-62
references: 18158304
references: Nat Genet. 2011 Mar 20;43(4):371-8
references: 21423181
references: Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15804-9
references: 20720163
references: Antisense Nucleic Acid Drug Dev. 2003;13(3):129-42
references: 12954113
references: Nucleic Acids Res. 2009 Sep;37(17):5784-92
references: 19596814
references: J Pharmacol Exp Ther. 2001 Mar;296(3):890-7
references: 11181921
references: Pharm Res. 2010 Sep;27(9):1788-99
references: 20424893
references: Biochem Biophys Res Commun. 2005 Feb 11;327(2):473-84
references: 15629139
references: Nucleic Acids Res. 2007;35(9):2885-92
references: 17439965
references: Nucleic Acids Res. 2006 May 11;34(8):2294-304
references: 16690972
references: Methods Enzymol. 2009;468:371-87
references: 20946778
references: Antisense Res Dev. 1995 Winter;5(4):241
references: 8746772
references: Nucleic Acid Ther. 2012 Jun;22(3):152-61
references: 22545703
references: Nucleic Acids Res. 2007;35(2):687-700
references: 17182632
references: Biochim Biophys Acta. 1999 Dec 10;1489(1):69-84
references: 10806998
references: Nucleic Acids Res. 1997 Nov 15;25(22):4429-43
references: 9358149
references: Nucleic Acid Ther. 2012 Oct;22(5):344-59
references: 22852836
references: J Biol Chem. 1979 Aug 25;254(16):7476-8
references: 224029
references: Anal Biochem. 2007 Jun 1;365(1):103-10
references: 17416339
references: Biochemistry. 2004 Mar 30;43(12):3537-54
references: 15035624
references: Nucleic Acids Res. 1988 Dec 23;16(24):11691-704
references: 2850541
references: Nucleic Acids Res. 2009 Jan;37(1):70-7
references: 19015151
references: ChemMedChem. 2010 Aug 2;5(8):1344-52
references: 20544786
references: Cell Cycle. 2010 Oct 15;9(20):4041-2
references: 20935480